Predictors of Pathological Complete Response to Neoadjuvant Treatment in Invasive Breast Cancer with Different Human Epidermal Growth Factor Receptor 2 (HER2) Subcategories

Overview

Journal Quant Imaging Med Surg

Specialty Radiology

Date 2024 Sep 16

PMID 39281175

Authors

Bo Sun

Yanbo Li

Jiahui Wang

Hong Lu

Junnan Li

Affiliations

Soon will be listed here.

Abstract

Background: Among human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients who receive anti-HER2 treatment, a noteworthy correlation between pathological complete response (pCR) and longer survival has been observed. The rate of pCR varies with the tumor's degree of HER2 protein expression. The aim of this study was to assess the correlations between clinicopathological characteristics, magnetic resonance imaging (MRI) parameters, and pCR in breast cancer with different HER2 subcategories.

Methods: A total of 281 invasive breast cancer patients diagnosed with HER2-positivity were included. HER2-positive translated to immunohistochemistry (IHC) 3+ or IHC 2+/fluorescence in situ hybridization (FISH)(+). All enrolled patients underwent baseline MRI examination and received neoadjuvant chemotherapy, dual anti-HER2 therapy, and subsequent therapeutic surgery from January 2021 to May 2022. A logistic regression model was used to evaluate the effects of covariates on pCR.

Results: Compared to the IHC 2+/FISH(+) group, patients with IHC 3+ tumors had a higher pCR rate (58.1% 26.7%, P<0.001), clinical stage (58.6% 40%, P=0.038), apparent diffusion coefficient (ADC) value (0.96 0.88 mm/s, P=0.004), and were more likely to be estrogen receptor (ER) negative (55.9% 31.1%, P=0.002) and progesterone receptor (PR) negative (72.5% 46.7%, P=0.001). In both groups, univariate analysis showed that the pCR group more often had ER-negative and PR-negative status than the non-pCR group (P<0.001). The final multivariable analysis showed that ER-negativity was associated with pCR in the IHC 2+/FISH(+) group (P=0.004). ER-negativity and the longest diameter were two independent predictors of pCR in the IHC 3+ group (P<0.001 for ER, P=0.026 for longest diameter).

Conclusions: The IHC 3+ group had a higher pCR rate than the IHC 2+/FISH(+) group. Along with clinicopathological characteristics, MRI parameters were supplemental predictors of pCR, particularly in IHC 3+ patients.

References

Atallah N, Alsaleem M, Toss M, Mongan N, Rakha E . Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level. Br J Cancer. 2023; 129(10):1692-1705. PMC: 10646129. DOI: 10.1038/s41416-023-02426-4. View

Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E . Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol. 1999; 17(1):110-9. DOI: 10.1200/JCO.1999.17.1.110. View

Allison K, Hammond M, Dowsett M, McKernin S, Carey L, Fitzgibbons P . Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020; 38(12):1346-1366. DOI: 10.1200/JCO.19.02309. View

Wolff A, Hammond M, Allison K, Harvey B, Mangu P, Bartlett J . Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018; 36(20):2105-2122. DOI: 10.1200/JCO.2018.77.8738. View

Schettini F, Pascual T, Conte B, Chic N, Braso-Maristany F, Galvan P . HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2020; 84:101965. PMC: 7230134. DOI: 10.1016/j.ctrv.2020.101965. View

Kaufman B, Mackey J, Clemens M, Bapsy P, Vaid A, Wardley A . Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM.... J Clin Oncol. 2009; 27(33):5529-37. DOI: 10.1200/JCO.2008.20.6847. View

Press M, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei D . HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. J Clin Oncol. 2016; 34(29):3518-3528. PMC: 5074347. DOI: 10.1200/JCO.2016.66.6693. View

Elston C, Ellis I . Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19(5):403-10. DOI: 10.1111/j.1365-2559.1991.tb00229.x. View

Harbeck N, Gluz O, Christgen M, Kates R, Braun M, Kuemmel S . De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and.... J Clin Oncol. 2017; 35(26):3046-3054. DOI: 10.1200/JCO.2016.71.9815. View

10.

Krystel-Whittemore M, Xu J, Brogi E, Ventura K, Patil S, Ross D . Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Breast Cancer Res Treat. 2019; 177(1):61-66. PMC: 6640097. DOI: 10.1007/s10549-019-05295-9. View

11.

Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T . HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2019; 112(1):46-54. PMC: 7850037. DOI: 10.1093/jnci/djz042. View

12.

Leithner D, Wengert G, Helbich T, Thakur S, Ochoa-Albiztegui R, Morris E . Clinical role of breast MRI now and going forward. Clin Radiol. 2017; 73(8):700-714. PMC: 6788454. DOI: 10.1016/j.crad.2017.10.021. View

13.

Hurvitz S, Martin M, Fraser Symmans W, Jung K, Huang C, Thompson A . Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2017; 19(1):115-126. DOI: 10.1016/S1470-2045(17)30716-7. View

14.

Hylton N, Blume J, Bernreuter W, Pisano E, Rosen M, Morris E . Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012; 263(3):663-72. PMC: 3359517. DOI: 10.1148/radiol.12110748. View

15.

Nitz U, Gluz O, Christgen M, Grischke E, Augustin D, Kuemmel S . De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ±.... Ann Oncol. 2017; 28(11):2768-2772. DOI: 10.1093/annonc/mdx494. View

16.

Jafri N, Newitt D, Kornak J, Esserman L, Joe B, Hylton N . Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy. J Magn Reson Imaging. 2013; 40(2):476-82. PMC: 4507716. DOI: 10.1002/jmri.24351. View

17.

Johnston S, Hegg R, Im S, Park I, Burdaeva O, Kurteva G . Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic.... J Clin Oncol. 2020; 39(1):79-89. DOI: 10.1200/JCO.20.01894. View

18.

Wang J, Yoon E, Krishnamurthy S . Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry. Ann Diagn Pathol. 2024; 70:152288. DOI: 10.1016/j.anndiagpath.2024.152288. View

19.

Razek A, Gaballa G, Denewer A, Nada N . Invasive ductal carcinoma: correlation of apparent diffusion coefficient value with pathological prognostic factors. NMR Biomed. 2010; 23(6):619-23. DOI: 10.1002/nbm.1503. View

20.

Hatakenaka M, Soeda H, Yabuuchi H, Matsuo Y, Kamitani T, Oda Y . Apparent diffusion coefficients of breast tumors: clinical application. Magn Reson Med Sci. 2008; 7(1):23-9. DOI: 10.2463/mrms.7.23. View